Background-When warfarin is interrupted for surgery, low-molecular-weight heparin is often used as bridging therapy.
O ral anticoagulant therapy presents a problem when the need for surgery arises because anticoagulation is associated with bleeding from the operative site, patients have an increased risk of thromboembolism when therapy is interrupted, and the antithrombotic effect of warfarin takes 4 to 5 days to recede after it is stopped and to reestablish after it is restarted. [1] [2] [3] To reduce the risk of thromboembolism, it is
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often recommended that such patients receive intravenous heparin before and after surgery during the period when they do not have a therapeutic effect from warfarin. 1,4 -6 The practice of giving perioperative heparin therapy to patients who have warfarin temporarily interrupted is referred to as bridging therapy. Intravenous heparin is attractive as bridging therapy because it has a rapid onset of action and a short half-life and because its use minimizes the amount of time in the perioperative period that patients are not anticoagulated. 7 The disadvantages of using intravenous heparin as bridging therapy are that it is costly because it requires admission to hospital and it may increase the risk of postoperative bleeding. It has been estimated that it costs more than $600 000 to prevent 1 thromboembolic event in patients with prosthetic heart valves receiving intravenous heparin as bridging therapy. 8 For these reasons, bridging therapy is usually reserved for patients who have a high risk of arterial embolism such as those who have mechanical heart valves or atrial fibrillation with additional risk factors. 4 -6 Despite its historical use in this situation, the efficacy and safety of bridging therapy with unfractionated heparin are unknown. 1 Low-molecular-weight heparin is usually given subcutaneously once or twice daily in fixed weight-adjusted doses without laboratory monitoring. The convenience of this regimen makes low-molecular-weight heparin suitable for use out of hospital, and it is now widely used to treat patients with acute deep vein thrombosis at home. 9 -11 Thus, therapeutic-dose low-molecular-weight heparin is an attractive alternative to intravenous heparin for bridging therapy. Although it is used in clinical practice, the efficacy and safety of bridging therapy with low-molecular-weight heparin are uncertain. 12, 13 There are concerns that bridging with lowmolecular-weight heparin may not be effective at preventing arterial embolism and may be associated with perioperative bleeding, 1 although therapeutic low-molecular-weight heparin has been shown to be superior to unfractionated heparin in patients with acute coronary syndrome. 14 To date, there are no large, prospective, multicenter trials of bridging therapy. We performed a prospective, multicenter cohort study to assess the efficacy and safety of bridging therapy with low-molecular-weight heparin initiated out of hospital in patients who had a high risk of arterial embolism.
Methods

Study Sample
Consecutive consenting patients who had a prosthetic heart valve or had atrial fibrillation and at least 1 major risk factor for cardiac embolism and who required temporary interruption of warfarin for elective noncardiac surgery or an invasive procedure were potentially eligible. Major risk factors for cardiac embolism with atrial fibrillation were defined as previous transient ischemic attack or stroke, high blood pressure, diabetes, age Ͼ75 years, or left ventricular dysfunction. Patients were excluded if there was evidence of active bleeding before warfarin was stopped, platelet count Ͻ100ϫ10 9 /L, planned eye surgery (excluding cataract surgery) or neurosurgery, life expectancy of Ͻ3 months, serum creatinine Ͼ150 mol/L, or presence of an active duodenal ulcer.
The study protocol was reviewed and approved by the Institutional Review boards of each participating center. Written informed consent was obtained from all patients. At the time of consent, all patients were registered with the coordinating center. The study was supported by an unrestricted grant from Pharmacia Corp.
Treatment Regimen
The treatment protocol was based on a pilot study, 15 consensus of the investigators, and previous assessment of warfarin reversal ( Figure) . 16 
Preoperative Management of Anticoagulation
Warfarin therapy was stopped 5 days before the procedure (ie, patients missed 5 doses). Dalteparin, a low-molecular-weight heparin, was administered at a dose of 200 IU/kg sc (maximum, 18 000 IU) the morning of the third and second days before the procedure. On the morning before surgery, a dalteparin dose of 100 IU/kg (maximum, 9000 IU) was used. A daily dose of 200 IU/kg with this low-molecular-weight heparin is the same as the dose used for initial treatment of acute venous thromboembolism. 9 On the day before surgery, an international normalized ratio (INR) was obtained. If the INR was Ͼ1.4, the patient was given 1 mg oral vitamin K. If the INR was Ͼ1.7, the patient was given 2 mg oral vitamin K. If vitamin K was given, the INR was repeated on the day of surgery. If the INR was Ͼ1.4 on the day of surgery, postponement of surgery was considered. Aspirin was stopped 7 days before surgery. All preoperative management was given as outpatient therapy.
Postoperative Management of Anticoagulation
If possible, warfarin was given the evening of surgery at twice the patient's usual daily dose. No low-molecular-weight heparin was given the day of surgery. The day after surgery, patients resumed their preoperative dosage of warfarin and started once-daily lowmolecular-weight heparin. Low-molecular-weight heparin (dalteparin) was administered at a dose of 200 IU/kg daily or at a set dose of 5000 IU daily if the physician judged that the patient was at high risk for postoperative bleeding. Low-molecular-weight heparin was continued for at least 4 days and until the INR was Ͼ1.9. The INR was measured on the second and fourth postoperative days. Patients did not remain in hospital to receive low-molecular-weight heparin if they were otherwise capable of being managed as outpatients. Low-molecular-weight heparin was administered to outpatients by the patient, a relative, or a nurse. In patients in whom it was required, aspirin was restarted the day after surgery.
Follow-Up
While in hospital, patients were assessed daily for bleeding and thrombosis. Patients were familiarized with the signs and symptoms of thrombosis and bleeding and were encouraged to call study personnel if either was suspected after leaving hospital. All patients were followed up for 3 months.
Outcome Measures
The primary efficacy outcome was the frequency of symptomatic arterial or venous thromboembolism from 5 days preoperatively (the first day that warfarin was not taken before surgery) until 90 days after surgery. Arterial thromboembolism was defined as ischemic stroke, transient ischemic attack, myocardial infarction, or systemic embolism. Venous thromboembolism was defined as deep vein thrombosis or pulmonary embolism as previously described. 10 The primary safety end point was major hemorrhage. Major hemorrhage was defined as (1) overt bleeding with a hemoglobin decrease of Ͼ20 g /L within a 24-hour period or transfusion of at least 2 units of blood; (2) intracranial, intraspinal, intraoccular, retroperitonial, or pericardial bleeding; and (3) fatal bleeding.
All suspected outcome events were reviewed by a central adjudication committee using predefined criteria.
Bridging protocol.
Kovacs et al Low-Molecular-Weight Heparin as Bridging Therapy
Statistical Analysis
The sample size was determined by the need to obtain reasonably precise estimates (ie, narrow 95% CIs) of the frequency with which thromboembolism and major bleeding occurred. With an expected frequency for thromboembolism of 1% (95% CI, 0.3 to 3.6) and for major bleeding of 5% (95% CI, 2.7 to 9.0), it was judged that a study of 200 patients would be necessary. The 95% CIs were calculated with the Wilson Score Method. 17
Results
Patients
Two hundred twenty-four eligible and consenting patients from 11 tertiary care academic centers were enrolled and registered with the coordinating center from January 2001 to October 2001. Seven patients were excluded: 5 for creatinine Ͼ150 mol/L, 1 for planned neurosurgery, and 1 for platelet count Ͻ100ϫ10 9 /L. No patients were lost to follow-up. The baseline characteristics are given in Table 1 . Mean age was 70 years; 62% were men. By chance, 112 patients had prosthetic valves, and 112 patients had atrial fibrillation without a prosthetic valve. The most common procedures were cardiac catheterization (nϭ42), genitourinary surgery (nϭ33), dental procedures (nϭ25), and major orthopedic surgery (nϭ25).
Perioperative Management
Fifteen patients (6.7%) had an INR of Ͼ1.5 on the day before their procedure and required vitamin K; however, no surgery was postponed ( Time to achieve INR Ն2.0 (range), 
Thromboembolism
Of the 224 patients, 8 (3.6%; 95% CI, 1.6 to 6.9) had an episode of thromboembolism between the time warfarin was stopped and 90 days after having surgery (Tables 3 and 4 ). Of these 8 episodes, 2 (0.9%; 95% CI, 0.2 to 3.2) were judged highly likely to be due to cardioembolism (a stroke on day 42 and a transient ischemic attack on day 14) (Table 4) , 5 were judged unlikely to be due to cardioembolism (5 myocardial infarctions), and 1 was judged not to be due to cardioembolism (a deep vein thrombosis). Four of the episodes of thromboembolism occurred in patients who had a delay between surgery and the restarting of warfarin because of intraoperative or early postoperative bleeding (including the transient ischemic attack mentioned above), and 2 occurred after warfarin was stopped because of bleeding during the 3-month postoperative follow-up period (including the stroke on day 42 
Bleeding
There were 15 major hemorrhages (6.7%; 95% CI, 4.1 to 10.8), of which 8 occurred intraoperatively or Ͻ6 hours postoperatively before warfarin or dalteparin were restarted and hence were unlikely to be related to bridging therapy (Table 3) . Five major bleeds (2.2%; 95% CI, 1.0 to 5.1), all in patients who were receiving full-dose low-molecular-weight heparin postoperatively, occurred within a week of operation/ surgery. One of these 5 bleeds occurred 2 days after a skin graft operation in a patient who had an INR of 1.5 on the day before surgery and did not receive oral vitamin K. Two major bleeds occurred Ͼ4 weeks after the operative procedure and 
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were unlikely to be related to bridging therapy. Finally, there were no episodes of major hemorrhage preoperatively.
Mortality
There were no deaths in the 3-month follow-up period.
Discussion
This prospective, multicenter cohort study found that patients with prosthetic heart valves or atrial fibrillation have a substantial risk of thromboembolism and bleeding when warfarin is temporarily interrupted and surgery is performed. Thromboembolism occurred in 3.6% and major bleeding occurred in 6.6% of patients within 3 months of surgery. However, of 8 episodes of thromboembolism, only 2 were judged to be due to cardioembolism. Five episodes of thrombosis were myocardial infarctions that were probably related to a high prevalence of coronary artery disease in this older population with known cardiac disease, although interruption of antithrombotic therapy may have contributed to these events. 18, 19 Of the 15 episodes of major bleeding, 8 occurred intraoperatively or immediately after surgery before low-molecular-weight heparin therapy was restarted. Because the last preoperative dose of low-molecular-weight heparin was reduced to half the usual daily dose and was given at least 24 hours before surgery, it is unlikely that bridging therapy contributed to these 8 bleeds. Finally, given that there were no preoperative events of thrombosis or bleeding, this aspect of the bridging protocol likely does not need modification for this patient population. However, use of bridging with fulldose low-molecular-weight heparin may have contributed to the 5 episodes of bleeding that occurred within a week of surgery. Because 2 of these 5 patients subsequently had thromboembolism, we cannot exclude the possibility that the higher postoperative low-molecular-weight heparin dose of the bridging therapy indirectly contributed to these thrombotic events. Three previous studies evaluated the use of low-molecularweight heparin as bridging therapy. 15, 20, 21 Of a total of 126 patients in those 3 studies, 1 had thromboembolism 15 and 2 had a major episode of bleeding. 20, 21 Strengths of the present study include its prospective design, use of explicit inclusion and exclusion criteria, registration and complete follow-up of all enrolled patients, standardized evaluation of outcomes by a central adjudication committee, and large size compared with previous studies that evaluated bridging therapy. For these reasons, the findings of this study are expected to be valid and generalizable.
The main limitation of this study is the lack of a comparison group. Without an untreated control group, we are unable to determine whether bridging therapy with lowmolecular-weight heparin reduced the frequency of thromboembolism or increased the frequency of bleeding. There is concern that low-molecular-weight heparin is ineffective at preventing stroke caused by atrial fibrillation 22 and at preventing thromboembolic complications associated with prosthetic heart valves during pregnancy. 23 Similarly, without a comparison group that received perioperative intravenous heparin, the relative efficacy and safety of bridging therapy using intravenous heparin and subcutaneous low-molecular-weight heparin are uncertain. Different patient subgroups may require different postoperative strategies that are determined by the patient's risk of cardioembolism and risk of hemorrhage (ie, the type of surgery). Despite the fact that this study lacks a control group, this is the first large, multicenter, prospective study of bridging therapy. To date, there remains no accepted standard for bridging therapy. 24 The protocol and outcomes from this study can serve as a basis for future randomized studies.
We conclude that bridging therapy with subcutaneous low-molecular-weight heparin is feasible, but the optimal approach to management of patients who require temporary interruption of warfarin for invasive procedures is uncertain and deserves evaluation by randomized controlled trials.
